We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Anna MacDonald

Anna MacDonald

Science Writer

Contact Us

After obtaining a first-class honours degree in biological sciences from the University of East Anglia, Anna worked as a scientific conference producer before joining Technology Networks. As part of her role, Anna helps to coordinate coverage, working with key opinion leaders from industry and academia to produce content across all communities.


Latest Content
A “Living Pharmacy” That Can Shift the Body’s Circadian Clock
Industry Insight

A “Living Pharmacy” That Can Shift the Body’s Circadian Clock

Many of us are familiar with the undesirable physical and mental effects of a disrupted sleep/wake cycle caused by traveling across multiple time zones or working irregular hours. A collaborative project designed to address these issues is working to develop a “living pharmacy” – a personalized, wireless and fully implantable device that can control the body’s circadian clock.
Celebrating 20 Years of Nucleofector® Technology
Industry Insight

Celebrating 20 Years of Nucleofector® Technology

We spoke with Archie Cullen, senior vice president and head of bioscience solutions, Lonza. In this interview, Archie discusses the evolution of the Nucleofector® Technology, highlighting how it has supported and propelled basic and applied research. He also explores some of the most recent developments in the Nucleofector® Platform’s exciting journey.
Harnessing the Therapeutic Potential of Muscimol
Industry Insight

Harnessing the Therapeutic Potential of Muscimol

Technology Networks recently spoke with Jeff Stevens, Psyched Wellness’s CEO, to learn more about muscimol, its therapeutic potential and how it compares to other psychedelics such as psilocybin.
Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry
Industry Insight

Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry

In this interview, David E. Olson discusses the potential commercial, clinical and scientific implications of non-hallucinogenic psychedelic compounds.
How CRISPR-Based Gene Engineering Is Helping To Accelerate Alzheimer’s Disease Research
Industry Insight

How CRISPR-Based Gene Engineering Is Helping To Accelerate Alzheimer’s Disease Research

To learn about some of the main challenges associated with generating a large library of edited iPSCs and the role that Synthego is playing in the iNDI project, we spoke to Synthego’s CSO, Dr Robert Dean.
Shaping the Future of Organoid Research
Industry Insight

Shaping the Future of Organoid Research

Molecular Devices recently unveiled a brand new, first-of-its-kind Organoid Innovation Center. In this interview, Susan Murphy tells us more about the Center and discusses the advantages of automating organoid culturing and screening workflows.
Trends, Applications and Advances in Spatial Transcriptomics
Industry Insight

Trends, Applications and Advances in Spatial Transcriptomics

In this interview, Dr George Emanuel discusses the power of spatial transcriptomic profiling and some of the biggest trends in the field.
The Ins and Outs of Psychedelic-Assisted Psychotherapy
Industry Insight

The Ins and Outs of Psychedelic-Assisted Psychotherapy

To learn more about psychedelic-assisted psychotherapy, the advantages it offers and some of the conditions it could help to treat, Technology Networks spoke with Dr Reid Robison, chief medical officer of Novamind, a mental health company specialized in psychedelic medicine.
Next-Generation Sequencing for SARS-CoV-2 Surveillance
Industry Insight

Next-Generation Sequencing for SARS-CoV-2 Surveillance

To gain some insights into the role of NGS in global SARS-CoV-2 surveillance, we spoke to Michelle Fraser, general manager, NGS for PerkinElmer. Michelle also explains how labs working in this area can increase their throughput, decrease associated costs and simplify the analysis of NGS data collected.
Advancing Research of Inflammatory Intestinal Diseases
Industry Insight

Advancing Research of Inflammatory Intestinal Diseases

We spoke to Dr Lorna Ewart, Emulate’s executive vice president of science, to learn more about the limitations of traditional inflammatory intestinal disease models, what makes the Colon Intestine-Chip a more relevant model and how it can be used to investigate potential drug targets.
Advertisement